Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with moderately-to-severely active rheumatoid arthritis who had received limited or no treatment with DMARDs: efficacy and safety results from the 52-week phase 3 RA-BEGIN study

Abstract

Abstract is not available.